[1]Talat N, Belgaumkar AP, Schulte KM.Surgery in Castleman's disease: a systematic review of 404 published cases[J].Ann Surg, 2012, 255(4):677-684[2]CASTLEMAN B, IVERSON L, MENENDEZ VP.Localized mediastinal lymphnode hyperplasia resembling thymoma[J].Cancer, 1956, 9(4):822-830[3]Chan KL, Lade S, Prince HM, et al.Update and new approaches in the treatment of Castleman disease[J]. J Blood Med, 2016, 7: 145-158.[4]Lin CY, Chang YL.Castleman's disease in the head and neck region: Meta-analysis of reported cases in Taiwan and literature review[J].Taiwan yi zhi, 2010, 109(12):913-920[5]张路, 李剑.病发病机制研究进展[J].中国医学科学院学报, 2016, 38(1):118-121[6]Leger-Ravet MB, Peuchmaur M, Devergne O, et al.Interleukin-6 gene expression in Castleman's disease[J].Blood, 1991, 78(11):2923-2930[7]Nishimoto N, Terao K, Mima T, et al.Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody,tocilizumab,in patients with rheumatoid arthritis and Castleman disease[J].Blood, 2008, 112(10):3959-3964[8]Turcotte LM, Correll CK, Reed RC, et al.Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance[J].Pediatr Blood Cancer, 2014, 61(4):737-739[9]Dupin N, Diss TL, Kellam P, et al.HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma[J].Blood, 2000, 95(4):1406-1412[10]de Vries I A, van Acht M M, Demeyere T B, et al.Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature[J].Radiation Oncology, 2010, 5(1):7-[11]Fajgenbaum DC, van Rhee F, Nabel CS.HHV-8-negative,idiopathic multicentric Castleman disease: novel insights into biology,pathogenesis,and therapy[J].Blood, 2014, 123(19):2924-2933[12]Liu AY, Nabel CS, Finkelman BS, et al.Idiopathic multicentric Castleman's disease: a systematic literature review[J].Lancet Haematol, 2016, 3(4):e163-e175[13]Bollig C, Moon S, Sujoy V, et al.Castleman disease of the parotid in childhood: a case report[J].Am J Otolaryngol, 2014, 35(4):517-519[14]Wang HW, Pittaluga S, Jaffe ES.Multicentric Castleman disease: Where are we now[J].Semin Diagn Pathol, 2016, 33(5):294-306[15]Cronin DM, Warnke RA.Castleman disease: an update on classification and the spectrum of associated lesions[J].Adv Anat Pathol, 2009, 16(4):236-246[16]Lai CH, Tsai JW, Lin JN, et al.Plasma-cell type Castleman's disease of the neck and lymphocyte-depletion Hodgkin lymphoma associated with intestinal intussusception in an AIDS patient[J].Wei mian yu gan ran za zhi, 2013, 46(3):234-236[17]Inada K, Hamazaki M.Localized Mediastinal Lymph-Node Hyperplasia Resembling Thymoma[J].Annals of Surgery, 1958, 147(3):409-413[18]Al Kadah B, Popov HH, Schick B, et al.Cervical lymphadenopathy: study of 251 patients[J].Eur Arch Otorhinolaryngol, 2015, 272(3):745-752[19]Linkhorn H, van der Meer G, Gruber M, et al.Castleman' s disease: An unusually young presentation resulting in delayed diagnosis of a neck mass[J]. Int J Pediatr Otorhinolaryngol, 2016, 86: 90-92.[20]Thakral B, Zhou J, Medeiros LJ.Extranodal hematopoietic neoplasms and mimics in the head and neck: an update[J].Hum Pathol, 2015, 46(8):1079-1100[21]Chronowski GM, Ha CS, Wilder RB, et al.Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy[J].Cancer, 2001, 92(3):670-676[22]Li YM, Liu PH, Zhang YH, et al.Radiotherapy of unicentric mediastinal Castleman's disease[J].Chin J Cancer, 2011, 30(5):351-356[23]江倩, 桂婷, 倪小兵, 等.头颈部多中心型病例[J].临床口腔医学杂志, 2014, 30(1):24-26[24]van Rhee F, Casper C, Voorhees PM, et al.A phase 2,open-label,multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease[J].Oncotarget, 2015, 6(30):30408-30419 |